Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement
30 nov. 2020 07h30 HE
|
Sunesis Pharmaceuticals, Inc.
Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in...
Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights
16 nov. 2020 16h05 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ended September 30, 2020. Loss from...
Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights
09 nov. 2020 07h00 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at...
Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
12 oct. 2020 07h00 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular...
Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences
03 sept. 2020 07h00 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor...
Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split
02 sept. 2020 12h48 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated...
Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights
11 août 2020 16h05 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020. Loss from...
Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights
04 août 2020 07h00 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30...
Sunesis Announces Pricing of $12 Million Offering of Common Stock
29 juil. 2020 09h05 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its...
Sunesis Announces Proposed Public Offering of Common Stock
28 juil. 2020 16h07 HE
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other conditions,...